Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Today’s Bad, Bear Market and Cullinan Oncology Providing 2023 Accomplishments and Financial Results

March 14, 2024 0

The Market Today the Stock Market is bearish and most of the biotech stocks are down …

Arcturus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update and Hosts a Conference Call

March 7, 2024 0

Arcturus Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call Before listening to the Conference …

Compugen Reports Fourth Quarter and Full Year 2023 Results

March 6, 2024 0

Compugen in the NEWS Compugen (CGEN) offered its fourth Quarter and full year 2023 results yesterday, …

BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

March 4, 2024 0

BioCardia Inc in the NEWS BioCardia, Inc. (BCDA), a biotechnology company focused on advancing late-stage cell therapy …

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

March 4, 2024 0

Akero Therapeutics Akero Therapeutics (AKRO) released preliminary topline week 96 results from HARMONY, a Phase 2b …

Prohost Letter #459 ~ NAFLD & NASH

March 3, 2024 0

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is …

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

February 29, 2024 0

Verrica Pharmaceuticals Verrica Pharmaceuticals (VRCA) is a dermatology therapeutics company developing medications for skin diseases. …

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

February 26, 2024 0

Krystal Biotech Today, February 26, 2024, Krystal Biotech (KRYS) firm announces its full year financial results …

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

February 23, 2024 0

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s (EMA’s) Committee …

CRISPR Therapeutics Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 Plus All You Need To Know About this Firm’s Capabilities

February 22, 2024 0

CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics (CRSP) has transformed from a …

Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024 0

Ionis Pharmaceuticals For three decades, Ionis Pharmaceuticals (IONS) invented medicines to treat serious diseases. Currently, Ionis …

Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results

February 16, 2024 0

Travere Therapeutics in the NEWS Yesterday, Feb. 15, 2024, Travere Therapeutics, Inc. (TVTX) reported its fourth …

Could Precision Biosciences Gene Editing Firm Become the Only Company to Cure the Life-Threatening HBV Resistant Infection

February 15, 2024 0

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness …

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit. See Also: CRISPR Therapeutics Advanced Steps

February 15, 2024 0

CRISPR Therapeutics Announcement Today, Feb. 15, 2024, CRISPR Therapeutics announced that members of its senior management …

Two Pieces of News from CRISPR Therapeutics Today

February 13, 2024 0

Crispr Therapeutics First NEWS As we learned from Vertex Pharmaceuticals (VRTX) in an earlier, posted press …

Vertex Pharmaceuticals: EC Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVYTM, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

February 13, 2024 0

European Commission Grants Conditional Marketing to Vertex Pharmaceuticals CASGEVY Tuesday Feb 13, 2024, Vertex Pharmaceuticals (VRTX) …

Regenxbio Product RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

February 9, 2024 0

Regenxbio Product RGX-121 Achieves Primary Endpoint From Regenxbio (RGNX) we learned that results from the Phase …

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

February 8, 2024 0

Madrigal Pharmaceuticals Publication in the New England Journal of Medicine Resmetirom is the first investigational medicine …

Published in Nature Communications: MiNK Therapeutics’ AgenT-797 Demonstrates Promising Results in the Treatment of Severe Acute Respiratory Distress

February 6, 2024 0

MiNK Therapeutics in the NEWS Today, February 6, 2024, MiNK Therapeutics (INKT) announced the publication of the …

Vera Therapeutics to Participate in Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and More

February 2, 2024 0

Vera Therapeutics to Participate in Guggenheim Healthcare Talks February 2, 2024, Vera Therapeutics, Inc. (VERA) announced …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Today’s Bad, Bear Market and Cullinan Oncology Providing 2023 Accomplishments and Financial Results

Arcturus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update and Hosts a Conference Call

Compugen Reports Fourth Quarter and Full Year 2023 Results

BioCardia Inc Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Prohost Letter #459 ~ NAFLD & NASH

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Krystal Biotech Announced Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

CRISPR Therapeutics Financial Results for Fourth Quarter and Full Year Ended December 31, 2023 Plus All You Need To Know About this Firm’s Capabilities

Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results

Could Precision Biosciences Gene Editing Firm Become the Only Company to Cure the Life-Threatening HBV Resistant Infection

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit. See Also: CRISPR Therapeutics Advanced Steps

Two Pieces of News from CRISPR Therapeutics Today

Vertex Pharmaceuticals: EC Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVYTM, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Regenxbio Product RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Published in Nature Communications: MiNK Therapeutics’ AgenT-797 Demonstrates Promising Results in the Treatment of Severe Acute Respiratory Distress

Vera Therapeutics to Participate in Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and More